Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Gateshead Health NHS Foundation Trust, Gateshead, United Kingdom.
Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
J Am Coll Cardiol. 2018 Apr 24;71(16):1781-1796. doi: 10.1016/j.jacc.2018.02.045.
Thyroid hormone (TH) receptors are present in the myocardium and vascular tissue, and minor alterations in TH concentration can affect cardiovascular (CV) physiology. The potential mechanisms that link CV disease with thyroid dysfunction are endothelial dysfunction, changes in blood pressure, myocardial systolic and diastolic dysfunction, and dyslipidemia. In addition, cardiac disease itself may lead to alterations in TH concentrations (notably, low triiodothyronine syndrome) that are associated with higher morbidity and mortality. Experimental data and small clinical trials have suggested a beneficial role of TH in ameliorating CV disease. The aim of this review is to provide clinicians dealing with CV conditions with an overview of the current knowledge of TH perturbations in CV disease.
甲状腺激素 (TH) 受体存在于心肌和血管组织中,TH 浓度的微小变化可影响心血管 (CV) 生理。将 CV 疾病与甲状腺功能障碍联系起来的潜在机制是内皮功能障碍、血压变化、心肌收缩和舒张功能障碍以及血脂异常。此外,心脏疾病本身可能导致 TH 浓度的改变(尤其是低三碘甲状腺原氨酸综合征),这与更高的发病率和死亡率相关。实验数据和小型临床试验表明,TH 在改善 CV 疾病方面具有有益作用。本综述的目的是为治疗 CV 疾病的临床医生提供 CV 疾病中 TH 紊乱的当前知识概述。